Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Taxus data previewed

This article was originally published in The Gray Sheet

Executive Summary

TAXUS IV reports major adverse event rate of 10.6% after 12 months compared with 19.8% for control, and sustained benefits in diabetics, Boston Scientific says. The paclitaxel-eluting stent will go before FDA panel review Nov. 20 [Editor's note: For information on a live broadcast or videotape of the FDA Circulatory System Devices Panel go to FDAAdvisoryCommittee.com, or contact Julie Robenson at 301-664-7203]...
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT019345

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel